Trial intelligence / Profile preview

PROSECT RP: Immunomodulatory Medications for Relapsing Polychondritis

NCT06941376Phase 2Recruiting

Sponsor: University of Pennsylvania
Start: Nov 2025
Primary completion: Jul 2027
Modality: Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 2, open-label trial of methotrexate, azathioprine, adalimumab, infliximab and tocilizumab in relapsing polychondritis (RP) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Efficacy of the study drugs for the treatment of relapsing polychondritis at 26 weeks. Started Nov 2025; status: recruiting.

Drugs

methotrexateazathioprineadalimumabinfliximabtocilizumab

Conditions

relapsing polychondritis (RP)

Beyond the preview

Go deeper on NCT06941376.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06941376.